Plain-English translation of NCT06875960 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This is a continuation study for people with lupus who completed one of two earlier research trials. If you finished one of those studies and your doctor thinks you're still benefiting from deucravacitinib, this trial lets you keep taking the medication rather than stopping it. The study is being run by Bristol-Myers Squibb to ensure patients can safely continue this treatment.
When a promising lupus treatment shows benefits in an earlier study, doctors want patients who are doing well to have access to it. This trial bridges the gap between finishing research studies and having the medication available through standard care, so you don't have to stop a treatment that's helping you.
You likely qualify if…
You likely don't qualify if…
If you qualify, you'll continue taking the same medication you were receiving in your earlier study. Your doctor will monitor how you're doing and watch for any side effects or changes in your lupus symptoms. The exact schedule of visits and check-ins will follow the study protocol, which is designed to keep you safe while you continue benefiting from treatment.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
United States